Rempart Asset Management Inc. Increases Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Rempart Asset Management Inc. increased its stake in Thermo Fisher Scientific Inc. by 15.9%, acquiring a total of 52,878 shares valued at approximately $21.44 million.
• Insider trading activity included CEO Marc N. Casper and EVP Gianluca Pettiti each selling 400 shares recently, indicating a slight decrease in their holdings.
• Brokerage firms are optimistic about the company's future, with Scotiabank raising its price target for Thermo Fisher Scientific to $590.00 and a consensus rating of "Moderate Buy" from 16 analysts.

Rempart Asset Management Inc. increased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 15.9% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 52,878 shares of the medical research company's stock after buying an additional 7,242 shares during the quarter. Thermo Fisher Scientific comprises about 4.1% of Rempart Asset Management Inc.'s holdings, making the stock its 13th largest position. Rempart Asset Management Inc.'s holdings in Thermo Fisher Scientific were worth $21,440,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Brighton Jones LLC grew its position in Thermo Fisher Scientific by 28.9% in the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock valued at $2,293,000 after buying an additional 988 shares during the last quarter. Revolve Wealth Partners LLC lifted its stake in shares of Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after acquiring an additional 20 shares during the period. Fifth Third Wealth Advisors LLC increased its stake in shares of Thermo Fisher Scientific by 1.0% during the first quarter. Fifth Third Wealth Advisors LLC now owns 7,037 shares of the medical research company's stock worth $3,502,000 after acquiring an additional 73 shares during the period. Mirador Capital Partners LP raised its holdings in Thermo Fisher Scientific by 3.3% during the first quarter. Mirador Capital Partners LP now owns 8,829 shares of the medical research company's stock worth $4,393,000 after purchasing an additional 280 shares in the last quarter. Finally, Czech National Bank lifted its position in Thermo Fisher Scientific by 5.9% in the first quarter. Czech National Bank now owns 87,854 shares of the medical research company's stock valued at $43,716,000 after purchasing an additional 4,920 shares during the period. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 400 shares of the stock in a transaction on Friday, September 5th. The stock was sold at an average price of $500.50, for a total value of $200,200.00. Following the transaction, the chief executive officer directly owned 113,762 shares in the company, valued at approximately $56,937,881. This represents a 0.35% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 30,066 shares of company stock valued at $14,182,963 in the last ninety days. Insiders own 0.33% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on TMO. Scotiabank raised Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price for the company in a research note on Friday, July 11th. Royal Bank Of Canada set a $561.00 price objective on Thermo Fisher Scientific and gave the stock an "outperform" rating in a research report on Tuesday, September 2nd. UBS Group upped their price target on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a research note on Thursday, July 24th. Evercore ISI decreased their price objective on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a report on Tuesday, July 8th. Finally, HSBC reaffirmed a "hold" rating and issued a $510.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Sixteen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and a consensus price target of $588.35.

Thermo Fisher Scientific Stock Up 1.1%

TMO stock opened at $464.18 on Monday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The company's 50 day simple moving average is $476.70 and its 200-day simple moving average is $447.15. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $623.77. The firm has a market capitalization of $175.28 billion, a PE ratio of 26.85, a P/E/G ratio of 2.52 and a beta of 0.75.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. The firm had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.Thermo Fisher Scientific's revenue was up 2.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific's payout ratio is presently 9.95%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.